glp-1 agonists for diabetes Clinical Focus on in Type 2 Mellitus Video: Non-insulin injectable antidiabetic drugs
Description
doi: 10.1210/en.2011-1464
Endocr Connect 10(7):R200R212
Low levels of F
Information available on dietary reference intakes for individuals using obesity medications is minimal 28 , and currently not well-evidenced
Consistent with this, certain effectors of the Wnt pathway, including lithium and -catenin, enhance Gcg expression in intestinal but not pancreas-derived cell lines, supposedly via inhibition of the glycogen synthase kinase-3beta (GSK-3beta) [132,133]
